2.1 Types of Vascular Access (AVF, AVG, CVC)

The Lifeline of Hemodialysis: Vascular Access Modalities

In the field of nephrology and extracorporeal renal replacement therapy, vascular access is universally recognized as the patient's 'lifeline.' Without a reliable, high-functioning vascular access, delivering adequate hemodialysis is physiologically impossible. The extracorporeal circuit requires a continuous and robust flow of blood—typically ranging from 300 to 500 milliliters per minute (mL/min)—to pass through the dialyzer for effective solute clearance and ultrafiltration. Because standard peripheral veins collapse under the negative pressure generated by the dialysis machine's blood pump, and peripheral arteries are too deep and dangerous to cannulate repeatedly, specialized surgical interventions are required. The three primary types of vascular access are the Arteriovenous Fistula (AVF), the Arteriovenous Graft (AVG), and the Central Venous Catheter (CVC). Each modality presents unique clinical characteristics, advantages, maturation timelines, and complication profiles.

The Arteriovenous Fistula (AVF): The Gold Standard

The Arteriovenous Fistula (AVF) is structurally created through a surgical anastomosis—a direct connection—between a native artery and a native vein, most commonly in the patient's non-dominant forearm (radiocephalic fistula) or upper arm (brachiocephalic fistula). When the high-pressure arterial blood is redirected into the low-pressure venous system, the vein undergoes physiological adaptation. The vessel wall thickens, and the lumen dilates to accommodate the increased blood volume and pressure, a process known as 'arterialization.'

Clinical Advantages of the AVF

The AVF is championed by the Kidney Disease Outcomes Quality Initiative (KDOQI) as the optimal access choice through the 'Fistula First' initiative. The primary advantage of an AVF is its longevity and durability; a well-matured fistula can function for years, and sometimes decades, with minimal interventions. Because it is constructed entirely from the patient's native biological tissue, there are no foreign materials introduced into the body. This intrinsic characteristic translates to the lowest risk of access-related infections among all modalities. Furthermore, AVFs are far less prone to thrombosis (clotting) compared to grafts and catheters, as the endothelial lining of the native vein naturally resists platelet aggregation.

Maturation Timeline and Challenges

Despite its superior long-term outcomes, the AVF requires substantial patience. The physiological process of maturation typically takes 6 to 12 weeks, and in some cases, up to several months. During this period, the vessel must develop sufficient diameter and wall thickness to withstand the trauma of repeated cannulation with large-gauge (14G to 17G) needles. The 'Rule of 6s' is the established clinical metric for evaluating AVF maturation: the fistula should have a blood flow greater than 600 mL/min, a diameter of at least 6 millimeters, be located no more than 6 millimeters below the skin surface, and this should be achieved by 6 weeks post-creation. A primary drawback of the AVF is the risk of primary failure, where the fistula fails to mature adequately for dialysis use, necessitating additional surgical revisions (e.g., superficialization) or alternative access placement.

The Arteriovenous Graft (AVG)

When a patient's native vasculature is too fragile, narrow, or compromised by conditions such as severe peripheral vascular disease, recurrent phlebitis, or extensive diabetes mellitus, an AVF may not be feasible. In these instances, the Arteriovenous Graft (AVG) serves as the primary surgical alternative. An AVG utilizes a synthetic conduit—most commonly made of expanded polytetrafluoroethylene (ePTFE)—to bridge the artery and the vein. This synthetic tube is tunneled through the subcutaneous tissue, creating a loop or straight configuration that can be palpated and cannulated.

Advantages of the AVG

The most prominent clinical advantage of the AVG is its rapid readiness for use. Unlike the AVF, which requires weeks of biological adaptation, a standard ePTFE graft typically requires only 2 to 4 weeks for the surrounding tissue to encapsulate the synthetic material, thereby preventing perigraft hematomas or seromas upon cannulation. Recent advancements in bioengineering have also introduced 'early-cannulation' or 'immediate-use' grafts, featuring specialized self-sealing elastomeric layers that allow for needle insertion within 24 to 72 hours post-surgery.

Complication Profile

The reliance on synthetic material introduces significant clinical vulnerabilities. The AVG exhibits a substantially higher propensity for stenosis (narrowing of the vessel) and subsequent thrombosis compared to native fistulas. Stenosis in grafts most frequently occurs at the venous anastomosis, where the synthetic material joins the native vein, driven by intimal hyperplasia (an aggressive overgrowth of smooth muscle cells in response to turbulent blood flow and compliance mismatch). Consequently, AVGs require frequent surveillance and interventional procedures, such as percutaneous transluminal angioplasty (PTA) or surgical thrombectomy, to maintain patency. Additionally, the presence of foreign material inherently elevates the risk of localized and systemic infections, requiring stringent aseptic protocols during every cannulation event.

The Central Venous Catheter (CVC)

The Central Venous Catheter (CVC) represents the most direct, yet most perilous, method of vascular access. A CVC is a dual-lumen polyurethane or silicone tube inserted directly into a large central vein—most commonly the internal jugular vein, though the femoral or subclavian veins may be utilized in emergent or anatomically restricted scenarios. The tip of the catheter is advanced into the right atrium or the superior vena cava, allowing for the rapid extraction and return of blood.

Temporary vs. Tunneled CVCs

CVCs are categorized into two structural classes. Non-tunneled (temporary) catheters are inserted directly through the skin into the vein and are reserved strictly for acute kidney injury, emergency dialysis, or short-term inpatient use. Tunneled catheters are routed subcutaneously for several centimeters before entering the vein and feature a Dacron cuff. This cuff incites a localized fibrotic tissue response, effectively anchoring the catheter in place and creating a mechanical barrier against bacterial migration along the subcutaneous tract. Tunneled CVCs are utilized when patients are awaiting fistula maturation, recovering from graft thrombectomies, or when all other access options have been exhausted.

The Clinical Burden of Catheters

The 'Catheter Last' directive underscores the severe clinical risks associated with CVC dependence. CVCs exhibit the highest morbidity and mortality rates of any access type. They are the leading cause of Catheter-Related Bloodstream Infections (CRBSIs), which can rapidly progress to sepsis, endocarditis, or osteomyelitis. Furthermore, CVCs frequently suffer from mechanical dysfunctions, including fibrin sheath formation and intraluminal thrombosis, which severely impede blood flow and compromise dialysis adequacy (Kt/V). Because the catheter occupies the lumen of a central vein, prolonged use frequently induces central venous stenosis, permanently compromising the venous drainage of the entire extremity and precluding future AVF or AVG creation on that side. Therefore, prioritizing the transition from a CVC to a permanent internal access is a paramount objective for the dialysis interdisciplinary team.